• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Selexis, Pandion Enter Antibody Service Agreement contractpharma
    March 17, 2021
    Selexis SA, a JSR Life Sciences company, has signed a service agreement with Pandion Therapeutics, Inc. to advance the development of Pandion’s PT627, a systemically-acting PD-1 agonist antibody for the potential treatment of autoimmune and ...
  • Merck signs agreement to buy Pandion Therapeutics for $1.85bn pharmaceutical-technology
    March 01, 2021
    Merck has agreed to acquire biotechnology company Pandion Therapeutics for approximately $1.85bn to expand its portfolio of autoimmune disease-targeting candidates.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service